ERBB2 and cancer: Within the TNBC subgroup, HER2‐low cancers demonstrated lower frequencies of Ki‐67 ≥ 20 (84.8% vs. 93.5%, p < 0.001) and grade 3 tumors (59.5% vs. 68.7%, p = 0.001).